[Compound Amino Acid Capsule (8-11) combined with L-carnitine for the treatment of asthenospermia]

What Was Tested

Researchers studied L-Carnitine in this randomized controlled trial publication.

To observe the clinical effect of combined application of Compound Amino Acid Capsule (8-11) (CAAC8-11) and L-carnitine (LC) in the treatment of idiopathic asthenospermia (IAS), and to explore its possible therapeutic mechanism.

Who Took Part

PubMed tags the participants as men only.

Based on the principle of double-blind and control, the researchers selected 120 cases of IAS meeting the diagnostic criteria of asthenospermia in the WHO Manual for the Examination and Processing of Human Semen (5th Ed) and randomly divided them into three groups of an equal number: CAAC8-11 + LC, LC control and blank control, the former given CAAC8-11 in addition to LC oral liquid, and the latter two given LC oral liquid and life intervention, respectively, all for 12 weeks.

The researchers collected semen samples from all the patients before and after treatment, and examined perm motility, the contents of neutral α- glucosidase (NAG) and reactive oxygen species (ROS), sperm DNA fragmentation index (DFI), and the expression of the Nrf2 protein.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this L-Carnitine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received L-Carnitine.

The methods mention a period of 12 weeks.

What Was Measured

Topics PubMed links to this paper include Carnitine, Amino Acids, Sperm Count, Semen, NF-E2-Related Factor 2, Reactive Oxygen Species and Sperm Motility.

The authors tagged it with the keywords infertility; asthenospermia; ROS; Nrf2; neutral α-glycosidase; DFI; Compound Amino Acid Capsule (8-11).

What This Means in Plain Language

The paper is a randomized and double-blind study of L-Carnitine over 12 weeks.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Zhonghua nan ke xue = National journal of andrology), a journal based in China.

More context: the L-Carnitine compound page, all human trials.